dimanche 15 novembre 2026
RechercherExplore
fr.via.news
Source trace. Via News points to the documents behind its reporting and shows what we drew from each, so you can check any claim. How we source
Source document· April 10, 2026

Wells Fargo Q1 Earnings on the Deck: What's in Store for the Stock?

View original at finance.yahoo.com
Wells Fargo Q1 Earnings on the Deck: What's in Store for the Stock? Wells Fargo & Company WFC is slated to report first-quarter 2026 earnings results on April 14, 2026, before market open…
Opening lines of the source · short snapshot: read the full document at the original

Ce que nous avons tiré de cette source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Net interest income expected to be $12.3 billion in Q1 2026, indicating 6.9% rise from year-ago quarter

    60% confidence

  • Investment advisory and other asset-based fee revenues expected to be $2.9 billion in Q1 2026, indicating 12.8% year-over-year rise

    60% confidence

  • Wells Fargo Q1 2026 earnings per share expected to be $1.57, representing 23.6% improvement from prior-year quarter

    60% confidence

  • Wells Fargo has outpaced earnings consensus estimates in the trailing four quarters with average surprise of 7.53%

    60% confidence

  • Wells Fargo Q1 2026 revenues expected to reach $21.73 billion, representing 7.8% year-over-year growth

    60% confidence

  • Demand for commercial and industrial and consumer loans was impressive in the first two months of Q1 2026, while real estate loan demand was subdued

    60% confidence

  • Mortgage banking revenues expected to be $283 million in Q1 2026, suggesting 14.8% decline from year-ago level

    60% confidence

Data points we hold from this source

Wells Fargo & Company · mortgage banking revenues283 USD
Wells Fargo & Company · investment advisory fee growth12.8 percent
Wells Fargo & Company · net interest income growth6.9 percent
Wells Fargo & Company · investment advisory fees2.9 USD
Ce que nous savons · l'intelligence derrière cette page
En direct du substrat
Ce que nous observons
Q4 2026 Biotech Catalyst Cluster: Late-Stage Data and PDUFA Dates Converge
Early-to-mid November 2026 is a dense run of clinical readouts and Q3 earnings at AHA, AASLD, ACR and ASH. Mid-cap biotechs (Vir, Mineralys, Arrowhead, Oryzon, Novartis, J&J) are reporting data that feeds into regulatory decisions. The next ones are the ivonescimab BLA (Nov 14) and the lorundrostat PDUFA (Dec 22), followed by ECLIPSE 2/3 and Maritime-1 readouts in Q1 2027. The list also includes an unrelated delisting track (EGM Nov 19, application Jan 25, 2027), and the facts have no AI or fintech content.
Notre lecture des données ›
Signaux que nous suivons
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Tendances que nous surveillons ›
Là où les sources divergent
Sources réconciliées : aucun conflit ouvert pour l'instant.
Nous signalons les conflits ouvertement ›
Vérifié récemment
✓ Vérifié avec la source d'origine
4,959
faits reliés à leur source, et nous signalons ceux qui ne tiennent pas.
101 entités suivies4,959 faits vérifiés avec la source5,585 documents sources archivés
Interrogez ces données → isubstrate.com
Wells Fargo Q1 Earnings on the Deck: What's in Store for the Stock?: Source | Via News | fr.via.news